At a glance
ClinicalIndex Comparison RecordPhase 3Recruiting· 468 target
Drug / intervention
HS-20089 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Open-label, Controlled, Phase III Clinical Study Evaluating HS-20089 vs. Investigator's Choice of Chemotherapy in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
In Brief
A Phase 3 clinical trial evaluating HS-20089, Paclitaxel, and 2 other interventions for Ovarian Cancer. Currently recruiting, targeting 468 participants across 1 site.
Detailed Summary
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of HS-20089 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesChina
Collaborators--
Timeline
Phase 3Recruiting
2026202720282029
First PostedMar 2025
Enrollment StartMar 2025
TodayJul 2026
Primary CompletionMar 2027
Study CompletionMar 2029
First PostedMar 3, 2025
Enrollment StartMar 13, 2025
Primary CompletionMar 7, 2027
Study CompletionMar 7, 2029
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 1.3 years agoPrimary completion in 8 months
Interventions
HS-20089drug
HS-20089 dose 1
Paclitaxeldrug
Paclitaxel dose 2
Doxorubicindrug
Doxorubicin dose 3
Topotecandrug
Topotecan dose 4